Thermo Fisher Scientific has launched the One Lambda HybriType HLA Plus Typing Flex kit. This next-generation sequencing (NGS) hybrid capture assay featuring a probe-based design that optimises read balance and uniformity is designed to provide flexibility in testing configuration and coverage, supporting human leukocyte antigen (HLA) genotyping analysis across various sample types, including whole blood and buccal swabs.
This testing kit aims to enable customers to perform deeper research into the major histocompatibility complex (MHC) that can impact various evolving conditions. Its simple workflow combined with One Lambda TypeStream Visual NGS Software enables rapid automated analysis.
Its flexible content and extensive gene coverage may minimize ambiguity, delivering results with ≥99.8% concordance. The streamlined workflow, taking less than 5.5 hours with under 2.5 hours of hands-on time, combined with One Lambda TypeStream Visual NGS Software, enables rapid automated analysis.
“We developed HybriType to enable our customers to perform deeper research into the major histocompatibility complex (MHC), a genetically rich region that plays a key role in histocompatibility and immunogenetics,” said Tina Liedtky, president, Transplant Diagnostics, Thermo Fisher Scientific. “As our knowledge of the human immune system and how the MHC may impact various conditions continues to evolve, we’re committed to providing our customers with the tools they need to further our collective understanding.”
